Similar articles

• Human menopausal gonadotropin and recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles.

  van Wely M, Westergaard LG, Bossuyt PM, van der Veen F. van Wely M, et al. Fertil Steril. 2003 Nov;80(5):1121-2. doi: 10.1016/s0015-0282(03)02190-3. Fertil Steril. 2003. PMID: 14607560 No abstract available.
• Methodologic pitfalls in assessing the efficacy of recombinant follicle-stimulating hormone versus human menopausal gonadotropin in assisted reproduction.

  Daya S. Daya S. Fertil Steril. 2003 Nov;80(5):1100-4. doi: 10.1016/s0015-0282(03)02193-9. Fertil Steril. 2003. PMID: 14607555 No abstract available.
• Conveying and discussing uncertainty- looking in both directions.

  Steiner AZ. Steiner AZ. Fertil Steril. 2004 Jul;82(1):256. doi: 10.1016/j.fertnstert.2004.04.010. Fertil Steril. 2004. PMID: 15237033 No abstract available.
• Recombinant human follicle-stimulating hormone versus urinary-derived human menopausal gonadotropin for controlled ovarian stimulation: the science and art of assisted reproductive technologies.

  Kelly E. Kelly E. Fertil Steril. 2003 Nov;80(5):1105-7. doi: 10.1016/s0015-0282(03)02186-1. Fertil Steril. 2003. PMID: 14607556 Review. No abstract available.
• Clinical efficacy of highly purified hMG versus recombinant FSH in IVF/ICSI cycles: a meta-analysis.

  Jee BC, Suh CS, Kim YB, Kim SH, Moon SY. Jee BC, et al. Gynecol Obstet Invest. 2010;70(2):132-7. doi: 10.1159/000308458. Epub 2010 Apr 10. Gynecol Obstet Invest. 2010. PMID: 20389096 Review.